Teva Stops Selling Generic Univasc
This article was originally published in The Pink Sheet Daily
Executive Summary
Agreement with Schwarz ends at-risk launch of the antihypertensive moexipril. Teva launched the generic in May 2003 after receiving a favorable patent ruling in federal district court.
You may also be interested in...
Teva Generic Univasc Patent Victory Vacated
Teva plans to continue distributing its generic version of Schwarz' Univasc despite an appeals court's Jan. 29 opinion vacating a noninfringement ruling for the company
Pink Sheet Podcast: Relyvrio And Public Promises, Allergy Biomarker Adcomms, PMDA In The USA
Pink Sheet reporters and editor discuss the implications of Amylyx following through on its pledge to remove Relyvrio from the market after its trial failed, an FDA idea to bring potential biomarkers for promising allergy and asthma treatments to advisory committees, and Japan’s PMDA opening an office in Washington D.C.
Pink Sheet Podcast: Mifepristone And Misinformation At SCOTUS, Understanding US FDA’s ODAC
Pink Sheet reporters and editor discuss the upcoming US Supreme Court arguments on mifepristone access, the SCOTUS reaction to the fight against misinformation, and the FDA’s Oncologic Drugs Advisory Committee going against three negative product reviews.